

## QUARTERLY FOCUS ISSUE: HEART RHYTHM DISORDERS

## Torsade de Pointes

# Late Na<sup>+</sup> Current Inhibition by Ranolazine Reduces Torsades de Pointes in the Chronic Atrioventricular Block Dog Model

Gudrun Antoons, PhD,\* Avram Oros, MD, PhD,\* Jet D. M. Beekman, BSc,\* Markus A. Engelen, MD,\*† Marien J. C. Houtman, BSc,\* Luiz Belardinelli, MD,§ Milan Stengl, PhD,\*‡ Marc A. Vos, PhD\*  
*Utrecht, the Netherlands; Munster, Germany; Plzen, Czech Republic; and Palo Alto, California*

- Objectives** This study investigated whether ranolazine reduces dofetilide-induced torsades de pointes (TdP) in a model of long QT syndrome with down-regulated K<sup>+</sup> currents due to hypertrophic remodeling in the dog with chronic atrioventricular block (cAVB).
- Background** Ranolazine inhibits the late Na<sup>+</sup> current (I<sub>NaL</sub>) and is effective against arrhythmias in long QT3 syndromes despite its blocking properties of the rapid component of delayed rectifying potassium current.
- Methods** Ranolazine was administered to cAVB dogs before or after TdP induction with dofetilide and electrophysiological parameters were determined including beat-to-beat variability of repolarization (BVR). In single ventricular myocytes, effects of ranolazine were studied on I<sub>NaL</sub>, action potential duration, and dofetilide-induced BVR and early afterdepolarizations.
- Results** After dofetilide, ranolazine reduced the number of TdP episodes from 10 ± 3 to 3 ± 1 (p < 0.05) and partially reversed the increase of BVR with no abbreviation of the dofetilide-induced QT prolongation. Likewise, pre-treatment with ranolazine, or using lidocaine as a specific Na<sup>+</sup> channel blocker, attenuated TdP, but failed to prevent dofetilide-induced increases in QT, BVR, and ectopic activity. In cAVB myocytes, ranolazine suppressed dofetilide-induced early afterdepolarizations in 25% of cells at 5 μmol/l, in 75% at 10 μmol/l, and in 100% at 15 μmol/l. At 5 μmol/l, ranolazine blocked 26 ± 3% of tetrodotoxin-sensitive I<sub>NaL</sub>, and 49 ± 3% at 15 μmol/l. Despite a 54% reduction of I<sub>NaL</sub> amplitude in cAVB compared with control cells, I<sub>NaL</sub> inhibition by 5 μmol/l tetrodotoxin equally shortened relative action potential duration and completely abolished dofetilide-induced early afterdepolarizations.
- Conclusions** Despite down-regulation of I<sub>NaL</sub> in remodeled cAVB hearts, ranolazine is antiarrhythmic against drug-induced TdP. The antiarrhythmic effects are reflected in concomitant changes of BVR. (J Am Coll Cardiol 2010;55:801–9) © 2010 by the American College of Cardiology Foundation

The voltage-dependent sodium channels produce a fast inward current upon depolarization that marks the initial upstroke of the cardiac action potential. Following activation, most channels rapidly inactivate, but some sustained activity remains: the late sodium current (I<sub>NaL</sub>) (1). I<sub>NaL</sub> is

up-regulated in heart failure (2,3), and inhibition of I<sub>NaL</sub> abolished early afterdepolarizations (EADs) in failing myocytes (4). A link between enhanced I<sub>NaL</sub> and proarrhythmia has been revealed by our understanding of the long QT3 syndrome: gain-of-function of Na<sup>+</sup> channels induces torsades de pointes (TdP) (5). These findings have renewed our interest in Na<sup>+</sup> channel blockers as potential antiarrhythmic strategy. Ranolazine is an antianginal agent that has been explored recently for its antiarrhythmic action. Its block against I<sub>NaL</sub> is more sensitive than for peak Na<sup>+</sup> current (6) and may be of importance in heart failure where conduction is already compromised (7). Ranolazine also blocks the rapid component of the delayed rectifying potassium current (I<sub>Kr</sub>) (8,9) and prolongs QT in patients (10), but it is not proarrhythmic (8,9,11) and shortens QT and suppresses arrhythmias in long QT3 syndrome (12–14).

From the \*Department of Medical Physiology, Division of Heart and Lungs, University Medical Center Utrecht, University of Utrecht, Utrecht, the Netherlands; †Cardiology and Angiology, Hospital of University Munster, Munster, Germany; ‡Physiology, Charles University, Faculty of Medicine in Plzen, Plzen, Czech Republic; and §Gilead Sciences, Inc., Palo Alto, California. This work was supported by a grant from the European Union FP6 (LSHM-CT-2005-018802, Contica), the Belgian Science Program IAP6/31, an unrestricted grant of Cardiovascular Therapeutics (CVT), and by a Veni grant from the Netherlands Organization for Scientific Research (916.56.145) to Dr. Antoons. Dr. Belardinelli is an employee of Gilead Sciences, Inc.

Manuscript received June 16, 2009; revised manuscript received September 23, 2009, accepted October 5, 2009.

**Abbreviations  
and Acronyms**

- APD** = action potential duration
- BVR** = beat-to-beat variability of repolarization
- cAVB** = chronic atrioventricular block
- EAD** = early afterdepolarization
- EB** = ectopic beat
- $I_{Kr}$**  = rapid component of the delayed rectifying potassium current
- $I_{Ks}$**  = slow component of the delayed rectifying potassium current
- $I_{NaL}$**  = sustained component of the sodium current referred to as late sodium current
- LQTS** = long QT syndrome
- MAPD** = monophasic action potential duration
- QTc** = corrected QT interval
- STV** = short-term beat-to-beat variability of LV (M)APD to quantify BVR
- TdP** = torsades de pointes
- TTX** = tetrodotoxin

Likewise, ranolazine stabilized repolarization in failing myocytes with prolonged repolarization and up-regulated  $I_{NaL}$  (15). Interestingly, ranolazine has been proven antiarrhythmic in long QT syndromes (LQTS) caused by mechanisms other than abnormal  $Na^+$  channel activity (16,17). Ranolazine also lowered incidence of arrhythmias in patients who survived an acute coronary syndrome (18), and first reports in patients with atrial fibrillation are promising (19).

The dog with chronic atrioventricular block (cAVB) model is well-characterized. Its high susceptibility to TdP relates to abnormal repolarization: down-regulation of  $K^+$  currents and up-regulation of  $Na/Ca$  exchange current (20). In this study, the effect of ranolazine on suppression and prevention of TdP induced by the  $I_{Kr}$  blocker dofetilide was tested and compared with lidocaine, an  $I_{Na}$  blocker with less selectivity than ranolazine for  $I_{NaL}$  over peak  $I_{Na}$  (21), but with no or much weaker inhibitory effects on  $I_{Kr}$  (22). Arrhythmogenic outcome was linked

to electrophysiological parameters, including beat-to-beat variability of repolarization (BVR) because of its high predictive value of TdP risk (23).

**Methods**

Animal handling was in accordance with the European Directive for the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes (86/609/EU). The experiments were approved by the Utrecht University Committee for Experiments on Animals.

**In vivo studies.** Thirty-two experiments were performed in 14 adult mongrel dogs with cAVB ( $24 \pm 3$  kg, Marshall, North Rose, New York). We used radiofrequency ablation to create AVB (24). Experiments were performed 4 weeks after AVB when electrical remodeling is completed (24). Details concerning anesthesia, animal care, data collection, and analysis have been described previously (25). Parameters were measured before the first extrasystolic beat or 10 min after dofetilide, ranolazine at 15 min, and lidocaine at 5 min after the start of infusion.


To induce TdP, cAVB dogs received a dose of 0.025 mg/kg dofetilide over 5 min or until TdP occurred within this period (Fig. 1A). Noninducible dogs ( $n = 3$ ) were excluded from further study. Ranolazine was given to 5 animals (Fig. 1A); a second group of 6 dogs received lidocaine (B. Braun Melsungen AG, Melsungen, Germany) at a dose of 3 mg/kg in 2 min. Six TdP-inducible cAVB dogs were used for serial testing (3 experiments) to determine the effect of ranolazine and lidocaine to prevent TdP induction (Fig. 2A).

**Cellular experiments.** For cell isolation, we refer to previous publication (26). Age-matched dogs with normal sinus rhythm served as control subjects. Action potentials were recorded at 0.5 Hz (Axopatch 200B, MDS Analytic Technologies, Sunnyvale, California) under whole-cell current-clamp using the perforated patch technique. Patch pipettes (resistance of 1 to 3 M $\Omega$ ) were filled with internal solution (in mmol/l): 130 KCl, 10 HEPES, 5 MgATP, 0.5 MgCl<sub>2</sub>, 10 NaCl, 1 CaCl<sub>2</sub>, 0.00026 amphotericin B, pH 7.20 using KOH. External solution contained (in mmol/l): 137 NaCl, 5.4 KCl, 0.5 MgCl<sub>2</sub>, 1.8 CaCl<sub>2</sub>, 11.8 HEPES, and 10 glucose, pH 7.40 with NaOH. Signals were low-pass filtered at 2 kHz and sampled at 4 kHz using a Digidata 1200 analog-to-digital converter and PClamp 9 software (MDS Analytic Technologies).

Whole-cell  $Na^+$  currents were measured in ruptured patch configuration. In the solutions,  $K^+$  was replaced by  $Cs^+$  to block  $K^+$  currents and nifedipine (20  $\mu$ mol/l) was added to block  $Ca^{2+}$  currents. The persistent component of the  $Na^+$  current,  $I_{NaL}$ , was measured as the tetrodotoxin (TTX)-sensitive current elicited by 500-ms depolarizing pulses from  $-130$  to  $-40$  mV. Interval between pulses was 30 s. The current amplitude was calculated by subtracting a current trace, recorded in the presence of 5- $\mu$ mol/l TTX from a trace under baseline, and was measured at the end of pulse. Membrane currents were sampled at 10 kHz and normalized to cell capacity (pA/pF). All experiments were done at 37°C.

**Plasma concentrations.** Blood samples were collected from a venous catheter every 5 min during experiment. Heparin-treated samples were centrifuged at 4,000 rpm at 4°C and stored at  $-80^\circ C$  for further analysis. Concentrations of ranolazine were determined using high-performance liquid chromatography at CV Therapeutics, Palo Alto, California.

**Statistics.** Data are expressed as mean  $\pm$  SEM. For comparisons between groups, unpaired Student *t* test was used. For dependent measurements, analysis of variance for repeated measurements was used with Bonferroni post-hoc testing. Number of ectopic beats and TdP episodes were compared using nonparametric Wilcoxon signed-ranks test or Friedman analysis of variance with Student-Newman-Keuls post-hoc testing for multiple comparisons. Statistical analysis was performed in SigmaStat version 3.10 (Systat Software, Inc., Chicago, Illinois). Values of  $p < 0.05$  were considered significant.




## Results

**Ranolazine reduces proarrhythmic activity in cAVB dogs.** Figure 1A shows a representative example of the ventricular rhythm at baseline (left), after dofetilide (middle), and with ranolazine (right). Dofetilide prolonged corrected QT interval (QTc), increased short-term beat-to-beat variability (STV), and induced TdP (Figs. 1B and 1C). Ranolazine significantly reduced the number of TdP episodes (Fig. 1B). This was associated with a reduction of STV, while QTc remained prolonged (Fig. 1C). Proarrhythmic activity was not completely suppressed by ranolazine, as evidenced by the presence of multiple ectopic beats (EBs) and TdP episodes (Figs. 1A and 1B) remaining in 4 of 5 dogs. Plasma levels of

ranolazine reached  $15.7 \pm 0.6 \mu\text{mol/l}$  at 10 min ( $n_{\text{dogs}} = 3$ ), which is comparable to values reported in a previous study with larger sample size (11).

In prevention experiments (Fig. 2A), ranolazine plasma levels reached a plateau at 5-min infusion and remained constant throughout the experiment; concentration was  $20 \pm 3 \mu\text{mol/l}$  at 15 min (Fig. 2B). Ranolazine alone did not produce significant changes in QTc or STV (Fig. 2C). Despite pre-administration of ranolazine, dofetilide prolonged QTc and tended to increase STV, but the latter increase was no longer significant (Fig. 2C, Table 1). Ranolazine reduced the number of dofetilide-induced TdP episodes (Fig. 2D). Albeit less frequently and of shorter duration, TdP was still seen in 4 of 6 dogs (Fig. 2D). The TdP duration was shortened from  $11 \pm 2$  s to  $5 \pm 2$  s ( $p <$



**Figure 2** Prevention of TdP After Ranolazine Pre-Treatment

(A) Flow chart. In the prevention experiment, the same dose of dofetilide was given as in control. Time between experiments was 2 weeks. (B) Plasma concentration of ranolazine. Arrows indicate start of 15-min ranolazine and 5-min dofetilide infusion. (C) Dofetilide-induced changes in QTc interval (left) and STV (right), before and after ranolazine (open circle vs. solid circles). \*p < 0.05 versus baseline. (D) Number of TdP episodes (left, #p < 0.05 dofetilide vs. dofetilide after ranolazine) and incidence (right) after ranolazine pre-treatment, n<sub>dogs</sub> = 6. Abbreviations as in Figure 1.

0.05). Single and multiple EBs occurred in the majority of animals (5 of 6).

**TdP suppression and prevention by lidocaine.** Suppression of dofetilide-induced TdP by lidocaine was studied in 6 animals using a similar protocol as described in Figure 1A for ranolazine. Results were comparable: lidocaine reduced the number of TdP episodes to 1.5 ± 2, and TdP remained

in 2 of 6 dogs. There was no shortening of the dofetilide-induced QTc prolongation (478 ± 17 ms to 514 ± 27 ms), but the antiarrhythmic effect was associated with a reduction of STV (3.7 ± 1.2 ms with dofetilide vs. 2.3 ± 0.4 ms with lidocaine, p < 0.05).

The results of the prevention experiments with lidocaine are summarized in Table 1. Lidocaine shortened the QTc interval,

**Table 1** Serial Electrophysiological and Proarrhythmic Properties of Dofetilide Before and After Ranolazine-Lidocaine

	Baseline 1	Dofetilide 1	Baseline 2	Ranolazine	Dofetilide 2	Baseline 3	Lidocaine	Dofetilide 3
R-R interval, ms	1,226 ± 148	1,254 ± 155	1,574 ± 102	1,676 ± 74	1,904 ± 141	1,499 ± 133	1,481 ± 129	1,481 ± 129
QT interval, ms	412 ± 29	577 ± 36*	442 ± 46	497 ± 45	644 ± 33†‡	425 ± 41	360 ± 25†	627 ± 41†‡
QTc, ms	392 ± 36	555 ± 39*	392 ± 38	438 ± 43	565 ± 31†‡	382 ± 34	318 ± 20†	586 ± 38†‡
LV MAPD, ms	334 ± 27	525 ± 34*	362 ± 49	410 ± 49	573 ± 56†‡	323 ± 41	281 ± 25	522 ± 51†‡
RV MAPD, ms	274 ± 21	361 ± 23*	330 ± 24	384 ± 24	503 ± 41†‡	270 ± 17	247 ± 14	352 ± 25†‡
ΔMAPD, ms	54 ± 4.3	147 ± 27*	53 ± 14	47 ± 15	73 ± 26	53 ± 29	36 ± 11	169 ± 44†‡
LV STV, ms	1.2 ± 0.1	3.1 ± 0.6*	1.6 ± 0.3	2.0 ± 0.3	3.3 ± 0.9	1.4 ± 0.3	1.2 ± 0.2	3.1 ± 0.4†‡
Single EBs	6 ± 3	62 ± 18*	1 ± 0.4	1 ± 1	84 ± 38	1 ± 0.3	0	27 ± 14
Multiple EBs	0	21 ± 8*	0	0	6 ± 3	0	0	2 ± 1§
nr TdPs	0	7 ± 2*	0	0	2 ± 1§	0	0	1 ± 1§
TdP incidence	0	6/6	0	0	4/6	0	0	3/6

There were no significant differences within the baseline data. \*p < 0.05 versus baseline 1; †versus baseline 2 to 3; ‡versus ranolazine-lidocaine; §versus dofetilide 1. EB = ectopic beat; LV = left ventricular; ΔMAPD = interventricular dispersion of repolarization duration; nr TdP = number of torsades de pointes/10 min; QTc = corrected QT interval; STV = short-term beat-to-beat variability of LV (M)APD to quantify BVR; TdP = torsades de pointes.

but failed to attenuate dofetilide-induced QT interval prolongation, increases in monophasic action potential duration (MAPD), interventricular dispersion, and STV. As with ranolazine, dofetilide-induced TdP episodes occurred less frequently in the presence of lidocaine, but were still observed in 3 of 6 cAVB dogs; multiple EBs were seen in 4 of 6 dogs.

Figure 3 summarizes individual data on STV according to arrhythmogenic outcome, defined as the occurrence of EBs or TdP. Effective prevention of arrhythmias either with lidocaine or ranolazine (n<sub>exp</sub> = 3) was associated with no change in STV, whereas an increase in STV preceded proarrhythmia (n<sub>exp</sub> = 7).


**Late Na<sup>+</sup> current is reduced in cAVB.** The late component of the Na<sup>+</sup> current was measured as the current sensitive to 5-μmol/l TTX (Fig. 4A, left). The amplitude of the inward current was significantly reduced in cAVB: -0.08 ± 0.01 vs. -0.173 ± 0.03 pA/pF in control cells (p < 0.05) (Fig. 4A, right). Despite its smaller amplitude, the TTX-sensitive

current equally contributed to APD in cAVB: 5-μmol/l TTX shortened APD<sub>90</sub> by 29 ± 3% in cAVB (n = 9) and by 28 ± 4% in control cells (n = 8, p = NS) (Fig. 4B).

Figure 4C shows the duration of successive APs and STV during the time course of a typical experiment where dofetilide was used to induce EADs, which were typically preceded by AP prolongation and an increase of STV. Addition of 5-μmol/l TTX fully suppressed EADs, and reversed the dofetilide-induced increase of APD and STV to baseline values.

**Suppression of afterdepolarizations by ranolazine is concentration-dependent.** In cAVB dogs, total ranolazine concentrations were between 7 and 30 μmol/l. Assuming that 65% of ranolazine is bound to plasma proteins, the calculated free drug concentration lies between 5 and 15 μmol/l. These concentrations were used for cellular experiments. The proportion of TTX-sensitive current blocked by ranolazine in cAVB was 26 ± 3% at 5 μmol/l (n = 6), and 49 ± 3% at 15 μmol/l (n = 8).

Figure 5A shows typical recordings of action potentials and dofetilide-induced EADs in a cAVB cell, with, in the lower panel, changes in APD and STV. Early afterdepolarizations were suppressed by 15 μmol/l (n<sub>cells</sub> = 9), although ranolazine did not shorten APD following dofetilide (p = 0.27), or significantly reduced STV (p = 0.13) (Fig. 5B). However, values were no longer different from baseline. In the particular example of Figure 5A, EADs were not suppressed by ranolazine when applied at 5 μmol/l. The concentration-dependent suppression of EADs by ranolazine is summarized in Figure 5C: in 25% of cAVB cells at 5 μmol/l (n = 4), versus 75% at 10 μmol/l (n = 4) and in 100% at 15 μmol/l (n = 9).




**Figure 3** Relation Between STV and Ectopic Activity/TdP (EB/TdP)

Individual changes of STV depicted under baseline, ranolazine (squares) or lidocaine (circles), and after dofetilide. Data are grouped according to ectopic beats (EBs) and/or TdP (+EB/TdP, closed symbols, n<sub>exp</sub> = 7; -EB/TdP, open symbols, n<sub>exp</sub> = 3). Abbreviations as in Figure 1.

## Discussion

In the cAVB dog model, ranolazine significantly suppressed and prevented dofetilide-induced TdP arrhythmias. However, BVR was only slightly reduced, in line with the observation that proarrhythmic activity was not completely



**Figure 4** Late Na<sup>+</sup> Current Is Reduced in cAVB

(A) Tetrodotoxin (TTX)-sensitive currents in control versus cAVB cells (left). Averaged data of current densities (pA/pF) in 6 control cells ( $n_{\text{dogs}} = 3$ ) and 12 cAVB cells ( $n_{\text{dogs}} = 4$ ,  $p < 0.05$ ) (right). (B) Relative action potential duration (APD<sub>90</sub>) in the presence of 5 μmol/l TTX in cAVB ( $n = 9$ ) versus control cells ( $n = 8$ , NS). (C) Time course of APD<sub>90</sub> (circles) and STV values (red line) is depicted under baseline, dofetilide (1 μmol/l), and TTX (5 μmol/l) in a cAVB cell. Addition of TTX started after the appearance of early afterdepolarizations (EADs) (indicated by arrow). Abbreviations as in Figure 1.


abolished. Lidocaine, a specific Na<sup>+</sup> blocker, had similar effects. An interesting finding of the present study was that inhibition of I<sub>NaL</sub> by TTX fully suppressed dofetilide-induced EADs in single cells, despite the fact that I<sub>NaL</sub> was down-regulated in cAVB. Ranolazine abolished EADs but only at higher concentrations. Thus the incomplete antiarrhythmic activity of ranolazine in cAVB dogs is not due to I<sub>Kr</sub> block, but more likely to reduced I<sub>NaL</sub> and concentration-dependent effects.

**Remodeling of I<sub>NaL</sub> in hypertrophy vs. heart failure.** The cAVB heart develops compensated hypertrophy, and electrical remodeling includes changes in delayed rectifying K<sup>+</sup> currents and Na/Ca exchange (27–29). Additionally, in the present study, we found a decrease of I<sub>NaL</sub>. This is at odds with heart failure, where I<sub>NaL</sub> is up-regulated despite smaller peak currents (2) and contributes to prolongation and abnormal repolarization (4). In cAVB, we previously reported lower messenger ribonucleic acid expression levels of cardiac Na<sup>+</sup> channels together with a reduction of peak current (30).

**Possible mechanisms underlying antiarrhythmic effects of ranolazine.** In vitro, the antiarrhythmic properties of ranolazine were reported at first in LQTS type 3 (13,14) and confirmed in failing myocytes with up-regulated I<sub>NaL</sub>

(15). Hence, the efficacy of ranolazine was ascribed to its I<sub>NaL</sub>-blocking properties. Interestingly, ranolazine was proven antiarrhythmic against EADs and TdP caused by mechanisms other than abnormal I<sub>NaL</sub>, including enhanced Ca<sup>2+</sup> channel activity mimicking the LQTS type 8 (16), and through inhibition of I<sub>Kr</sub> as a model for the LQTS type 2 (8). Reduced transmural dispersion as well as a decrease of repolarization variability were proposed as antiarrhythmic mechanisms (13,15,16). BVR originates in the plateau phase of the action potential and I<sub>NaL</sub> may indeed contribute to variability (31). In cAVB, ranolazine attenuated changes in dofetilide-induced BVR, but only to a limited extent.

Ranolazine prevents excessive Ca<sup>2+</sup> loading of the cell by lowering Na<sup>+</sup> levels through inhibition of I<sub>NaL</sub> (32). In cAVB, Na<sup>+</sup> levels are high, which enhances Ca<sup>2+</sup> loading (33). The subsequent increase of sarcoplasmic reticulum Ca<sup>2+</sup> release may facilitate EADs by promoting inward Na/Ca exchange current allowing Ca<sup>2+</sup> window currents to develop, and more Ca<sup>2+</sup> channels may be available for reactivation due to a larger recovery from release-dependent inactivation (28,34). In addition, high Ca<sup>2+</sup> loads favor spontaneous Ca<sup>2+</sup> release and delayed afterdepolarizations (27). By reversing the increased Na<sup>+</sup> levels, ranolazine may reduce triggered activity in cAVB.



**Figure 5** Ranolazine Suppression is Concentration-Dependent

(A) Action potentials in a cAVB cell are shown during ranolazine following dofetilide-induced EADs. The lower panel shows time-dependent changes in APD<sub>90</sub> (circles), STV (red line), and EAD occurrence. Early afterdepolarizations continued with 5-μmol/l ranolazine, but disappeared completely with 15 μmol/l. (B) APD<sub>90</sub> (upper) and STV (lower). Averaged data from 9 cAVB cells (n<sub>dogs</sub> = 5), \*p < 0.05 versus baseline. (C) Proportion of cAVB cells showing EAD suppression at different concentrations of ranolazine. Abbreviations as in Figures 1 and 4.

**Limited antiarrhythmic potential of Na<sup>+</sup> channel blockers in cAVB.** Although TdP occurs less, ranolazine did not completely abolish ectopic activity. At the therapeutic range, ranolazine blocks I<sub>Kr</sub> (8). In the remodeled cAVB heart with reduced repolarization reserve, an additional block of I<sub>Kr</sub> could confound the antiarrhythmic effects of ranolazine through inhibition of I<sub>NaL</sub>. Incomplete antiarrhythmic activity, however, was also seen with lidocaine. This agent has no inhibitory effects on I<sub>Kr</sub> at clinically relevant concentrations and is considered a selective blocker of I<sub>Na</sub> (22). It is therefore unlikely that the I<sub>Kr</sub> block contributes to the incomplete antiarrhythmic potential of ranolazine.

The main target for ranolazine, I<sub>NaL</sub>, is decreased and not increased in the cAVB heart. The block of I<sub>NaL</sub> by ranolazine is insufficient to balance the down-regulation of repolarizing

K<sup>+</sup> currents (I<sub>Ks</sub> [slow component of the delayed rectifying potassium current], I<sub>Kr</sub>) and ranolazine therefore cannot completely prevent or suppress proarrhythmia. On the other hand, in conditions with increased I<sub>NaL</sub> (LQTS type 3, heart failure) the block of I<sub>NaL</sub> should be sufficient as documented in LQTS type 3 (12,14) and/or heart failure (15).

Interestingly, in single cells, 15-μmol/l ranolazine fully suppressed EADs, whereas lower concentrations of 5 μmol/l could not. This concentration-dependent effect was also observed by others (8). On a background of down-regulated I<sub>NaL</sub>, the higher degree of Na<sup>+</sup> block might be required to tip the balance toward strengthened repolarization preventing the development of EADs despite blockage of I<sub>Kr</sub>. In the intact animal, the concentration of available ranolazine is likely less and below the critical level

for complete suppression of EADs. Higher plasma concentrations such as 20  $\mu\text{mol/l}$  would far exceed the therapeutic range (2 to 6  $\mu\text{mol/l}$ ) and could experimentally not be achieved in the dog.

**BVR.** BVR is a reliable parameter to predict drug-induced TdP and is superior to QT interval prolongation. A torsadogenic drug increases BVR, and this is independent of total duration of repolarization; a drug that does not increase BVR is considered safe (20). Fewer studies have addressed the potential of BVR for predicting successful antiarrhythmic treatment, where one expects a decrease and/or prevention of BVR increase if the drug is antiarrhythmic (35). The strong antiarrhythmic activity of the  $\text{Ca}^{2+}$  channel antagonist flunarizine, evidenced by complete inhibition of arrhythmogenic events, is associated with full reversal of BVR to baseline levels and lack of increase upon an arrhythmogenic challenge (36) and is in support of this premise. This finding is unlike the modest effects of  $\text{Na}^+$  blockers on BVR, which correspond to the inability of the blockers to fully prevent or suppress EBs and TdP. Proarrhythmic outcome was related to an increase of BVR in the susceptible animal and confirms the value of BVR as a marker of proarrhythmic risk. BVR was reflected already in ectopic beat formation (Fig. 3). In the noninducible animals, there was no change of BVR.

**Clinical implications.** The observation that ranolazine did not produce any proarrhythmic effects, rather was antiarrhythmic against dofetilide-induced TdP and EADs, further substantiates that ranolazine is a safe drug despite  $\text{I}_{\text{Kr}}$ -blocking properties. The concentration at which maximal antiarrhythmic effects were seen in the setting of reduced  $\text{I}_{\text{NaL}}$  in the cAVB model (15  $\mu\text{mol/l}$ ) was approximately 1.5 to 3 times higher than the clinical therapeutic concentrations. Yet, antiarrhythmic efficacy at therapeutic concentrations has been documented in the MERLIN-TIMI 36 (Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis In Myocardial Infarction 36) trial (18).

## Conclusions

The antiarrhythmic properties of ranolazine are most obvious under conditions of abnormal and increased  $\text{I}_{\text{NaL}}$ , including LQTS type 3. Albeit with less efficacy, ranolazine and other  $\text{Na}^+$  blockers are also antiarrhythmic against EADs and TdP in cAVB dogs with acquired LQTS, despite down-regulation of  $\text{I}_{\text{NaL}}$  due to remodeling. Antiarrhythmic effects were reflected in BVR, in single myocytes as well as in the intact animal.

**Reprint requests and correspondence:** Dr. Marc A. Vos, Department of Medical Physiology, Division Heart and Lungs, UMC Utrecht, Yalelaan 50, 3584 CM Utrecht, the Netherlands. E-mail: M.A.Vos@umcutrecht.nl.

## REFERENCES

1. Kiyosue T, Arita M. Late sodium current and its contribution to action-potential configuration in guinea-pig ventricular myocytes. *Circ Res* 1989;64:389-97.
2. Valdivia CR, Chu WW, Pu J, et al. Increased late sodium current in myocytes from a canine heart failure model and from failing human heart. *J Mol Cell Cardiol* 2005;38:475-83.
3. Maltsev VA, Sabbah HN, Higgins RS, Silverman N, Lesch M, Undrovinas AI. Novel, ultraslow inactivating sodium current in human ventricular cardiomyocytes. *Circulation* 1998;98:2545-52.
4. Maltsev VA, Silverman N, Sabbah HN, Undrovinas AI. Chronic heart failure slows late sodium current in human and canine ventricular myocytes: implications for repolarization variability. *Eur J Heart Fail* 2007;9:219-27.
5. Bennett PB, Yazawa K, Makita N, George AL Jr. Molecular mechanism for an inherited cardiac arrhythmia. *Nature* 1995;376:683-5.
6. Fredj S, Sampson KJ, Liu HJ, Kass RS. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action. *Br J Pharmacol* 2006;148:16-24.
7. Akar FG, Spragg DD, Tunin RS, Kass DA, Tomaselli GF. Mechanisms underlying conduction slowing and arrhythmogenesis in non-ischemic dilated cardiomyopathy. *Circ Res* 2004;95:717-25.
8. Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. *Circulation* 2004;110:904-10.
9. Schram G, Zhang LM, Derakhchan K, Ehrlich JR, Belardinelli L, Nattel S. Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects. *Br J Pharmacol* 2004;142:1300-8.
10. Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. *J Am Coll Cardiol* 2004;43:1375-82.
11. Beekman HDM, Antoons G, Oosterhoff P, et al. Alterations in T-wave morphology caused by ranolazine are not pro-arrhythmic in dofetilide susceptible chronic AV-block dogs. *Eur Heart J* 2006;27:722.
12. Moss AJ, Zareba W, Schwarz KQ, Rosero S, McNitt S, Robinson JL. Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome. *J Cardiovasc Electrophysiol* 2008;19:1289-93.
13. Song YJ, Shryock JC, Wu L, Belardinelli L. Antagonism by ranolazine of the pro-arrhythmic effects of increasing late  $\text{I}_{\text{Na}}$  in guinea pig ventricular myocytes. *J Cardiovasc Pharmacol* 2004;44:192-9.
14. Wu L, Shryock JC, Song YJ, Li Y, Antzelevitch C, Belardinelli L. Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome. *J Pharmacol Exp Ther* 2004;310:599-605.
15. Undrovinas AI, Belardinelli L, Undrovinas N, Sabbah HN. Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. *J Cardiovasc Electrophysiol* 2006;Suppl 1:S169-77.
16. Sicouri S, Timothy KW, Zygmunt AC, et al. Cellular basis for the electrocardiographic and arrhythmic manifestations of Timothy syndrome: effects of ranolazine. *Heart Rhythm* 2007;4:638-47.
17. Wang WQ, Robertson C, Dhalla AK, Belardinelli L. Antitorsadogenic effects of (+/-)-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits. *J Pharmacol Exp Ther* 2008;325:875-81.
18. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Skene A, McCabe CH, Braunwald E. Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial. *Am Heart J* 2006;152:400-6.
19. Murdock DK, Overton N, Kersten M, Kaliebe J, Devecchi F. The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation. *Indian Pacing Electrophysiol J* 2008;8:175-81.
20. Oros A, Beekman JDM, Vos MA. The canine model with chronic, complete atrio-ventricular block. *Pharmacol Ther* 2008;119:168-78.
21. Dumaine R, Kirsch GE. Mechanism of lidocaine block of late current in long Q-T mutant  $\text{Na}^+$  channels. *Am J Physiol Heart Circ Physiol* 1998;43:H477-87.
22. Paul AA, Witchel HJ, Hancox JC. Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine. *Br J Pharmacol* 2002;136:717-29.



23. Thomsen MB, Verduyn SC, Stengl M, et al. Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs. *Circulation* 2004;110:2453–9.
24. Schoenmakers M, Ramakers C, van Opstal JM, Leunissen JDM, Londono C, Vos MA. Asynchronous development of electrical remodeling and cardiac hypertrophy in the complete AV block dog. *Cardiovasc Res* 2003;59:351–9.
25. Vos MA, de Groot SH, Verduyn SC, et al. Enhanced susceptibility for acquired torsade de pointes arrhythmias in the dog with chronic, complete AV block is related to cardiac hypertrophy and electrical remodeling. *Circulation* 1998;98:1125–35.
26. Volders PGA, Sipido KR, Vos MA, Kulcsar A, Verduyn SC, Wellens HJJ. Cellular basis of biventricular hypertrophy and arrhythmogenesis in dogs with chronic complete atrioventricular block and acquired torsade de pointes. *Circulation* 1998;98:1136–47.
27. de Groot SH, Schoenmakers M, Molenschot MM, Leunissen JD, Wellens HJ, Vos MA. Contractile adaptations preserving cardiac output predispose the hypertrophied canine heart to delayed afterdepolarization-dependent ventricular arrhythmias. *Circulation* 2000;102:2145–51.
28. Sipido KR, Volders PGA, de Groot SH, et al. Enhanced  $Ca^{2+}$  release and Na/Ca exchange activity in hypertrophied canine ventricular myocytes: a potential link between contractile adaptation and arrhythmogenesis. *Circulation* 2000;102:2137–44.
29. Volders PGA, Sipido KR, Vos MA, et al. Downregulation of delayed rectifier  $K^+$  currents in dogs with chronic complete atrioventricular block and acquired torsades de pointes. *Circulation* 1999;100:2455–61.
30. Boulaksil M, Jungschleger J, Antoons G, et al. Torsade de pointes arrhythmias in the chronic AV-block dog are not determined by changes in conduction nor dominated by reentrant mechanisms. *Eur Heart J* 2009;30:554.
31. Zaniboni M, Pollard AE, Yang L, Spitzer KW. Beat-to-beat repolarization variability in ventricular myocytes and its suppression by electrical coupling. *Am J Physiol Heart Circ Physiol* 2000;278:H677–87.
32. Fraser H, Belardinelli L, Wang LG, Light PE, McVeigh JJ, Clanchan AS. Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts. *J Mol Cell Cardiol* 2006;41:1031–8.
33. Verdonck F, Volders PGA, Vos MA, Sipido KR. Increased  $Na^+$  concentration and altered Na/K pump activity in hypertrophied canine ventricular cells. *Cardiovasc Res* 2003;57:1035–43.
34. Antoons G, Volders PG, Stankovicova T, et al. Window  $Ca^{2+}$  current and its modulation by  $Ca^{2+}$  release in hypertrophied cardiac myocytes from dogs with chronic atrioventricular block. *J Physiol* 2007;579:147–60.
35. Thomsen MB, Volders PGA, Beekman JDM, Matz J, Vos MA. Beat-to-beat variability of repolarization determines proarrhythmic outcome in dogs susceptible to drug-induced torsades de pointes. *J Am Coll Cardiol* 2006;48:1268–76.
36. Oros A, Antoons G, Oosterhoff P, Attevelt N, Beekman HDM, Vos MA. The capacity of the heart to withstand an arrhythmic challenge increases with flunarizine which can be quantified using beat-to-beat variability of repolarization. *Eur Heart J* 2007;28:400–1.

---

**Key Words:** arrhythmias ■ long QT syndromes ■ sodium channels ■ antiarrhythmic agents.